Colorectal Carcinoma with Extremely Low CA19-9

被引:2
|
作者
Kawamura, Yutaka J. [1 ]
Tokumitsu, Aika [1 ]
Sasaki, Junichi [1 ]
Tsujinaka, Shingo [1 ]
Maeda, Takafumi [1 ]
Mizogami, Ken [1 ]
Konishi, Fumio [1 ]
机构
[1] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Omiya Ku, Saitama 3308503, Japan
关键词
PREOPERATIVE SERUM-LEVEL; FOLLOW-UP; CURATIVE RESECTION; PROGNOSTIC INDICATOR; TUMOR-MARKERS; CEA; CANCER; CA-19-9; SURGERY; RECURRENCE;
D O I
10.1155/2009/780263
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim. The aim of this study is to determine the significance of postoperative sequential measurements of serum CA19-9 in patients with extremely low serum level. Patients and Methods. Serum level of CA19-9 of 1096 patients who underwent surgery was measured preoperatively and every three months after surgery for 5 years. Patients with CA19-9 level of less than 2 U/mL at the time of diagnosis were defined as Extremely Low CA19-9 (ELCA). Results. One hundred and seven patients (9.8%) were ELCA. Of these, 86 underwent surgery with curative intent. Serum levels of CA19-9 in patients who did not undergo curative resection (N = 12) and who developed recurrence (N = 10) were less than 2.0 U/mL in all occasions during followup. In all patients without recurrence, serum level of CA19-9 also remained less than 2.0 U/mL. Conclusion. In patients with extremely low CA19-9, who consist of 9.8% of colorectal carcinoma cases, postoperative sequential measurement of serum level of CA19-9 contributed neither to assessment of curability of surgical resection nor to detection of recurrence. Copyright (C) 2009 Yutaka J. Kawamura et al.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Methylated septin 9 as a progression parameter in colorectal cancer compared to CEA and CA19-9
    Schulz, Laura
    Leerhoff, Sabine
    Kolbe, Ernst W.
    Raem, Arnold M.
    Winde, Gunther
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 64 - 65
  • [32] The use of Carbohydrate Antigen 19-9 (Ca19-9) in Diagnosis and Follow up of Colorectal Cancer
    Farrell, I.
    Smart, C.
    BRITISH JOURNAL OF SURGERY, 2015, 102 : 190 - 190
  • [33] CA19-9和CA50
    渡边弘之
    韩少良
    日本医学介绍, 2005, (02) : 55 - 56
  • [34] Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma
    Chen, Rui-Qiu
    Zhang, Zhi-Lei
    Jia, Yu-Ming
    Chen, Rui-Xiang
    Peng, Li
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [35] The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma
    Matsui, Satoshi
    Yamamoto, Yusuke
    Okamura, Yukiyasu
    Ito, Takaaki
    Ashida, Ryo
    Ohgi, Katsuhisa
    Yamada, Mihoko
    Otsuka, Shimpei
    Uesaka, Katsuhiko
    Sugiura, Teiichi
    ANTICANCER RESEARCH, 2022, 42 (06) : 3169 - 3176
  • [36] Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma
    Rui-Qiu Chen
    Zhi-Lei Zhang
    Yu-Ming Jia
    Rui-Xiang Chen
    Li Peng
    BMC Gastroenterology, 23
  • [37] CA50 AS A SERUM MARKER FOR PANCREATIC-CARCINOMA - COMPARISON WITH CA19-9
    PASQUALI, C
    SPERTI, C
    DANDREA, AA
    COSTANTINO, V
    FILIPPONI, C
    PEDRAZZOLI, S
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (07) : 1042 - 1043
  • [38] COMBINED ASSAY OF SERUM LEVELS OF CA125 AND CA19-9 IN ENDOMETRIAL CARCINOMA
    TAKESHIMA, N
    SHIMIZU, Y
    UMEZAWA, S
    HIRAI, Y
    CHEN, JT
    FUJIMOTO, I
    YAMAUCHI, K
    HASUMI, K
    GYNECOLOGIC ONCOLOGY, 1994, 54 (03) : 321 - 326
  • [39] CA19-9 - A PROMISING TUMOR-MARKER FOR PANCREATIC-CARCINOMA
    SAKAHARA, H
    ENDO, K
    NAKAJIMA, K
    HIDAKA, A
    NAKASHIMA, T
    OHTA, H
    TORIZUKA, K
    NAITO, A
    SUZUKI, T
    JOURNAL OF NUCLEAR MEDICINE, 1984, 25 (05) : P9 - P9
  • [40] Urinary Level of CA19-9 as a Tumor Marker in Urothelial Carcinoma of the Bladder
    Pal, Keya
    Roy, Suparna
    Mondal, Samim Ali
    Chatterjee, Uttara
    Tiwari, Punit
    Bera, Malay
    UROLOGY JOURNAL, 2011, 8 (03) : 203 - 208